Premium
French updated recommendations in Stage I to III melanoma treatment and management
Author(s) -
Guillot B.,
Dalac S.,
Denis M.G.,
Dupuy A.,
Emile J.F.,
De La Fouchardiere A.,
Hindie E.,
Jouary T.,
Lassau N.,
Mirabel X.,
Piperno Neumann S.,
De Raucourt S.,
Vanwijck R.
Publication year - 2017
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.14064
Subject(s) - stage (stratigraphy) , medicine , sentinel lymph node , melanoma , radiation therapy , sentinel node , general surgery , principal (computer security) , surgery , cancer , computer science , breast cancer , operating system , cancer research , paleontology , biology
As knowledge continues to develop, regular updates are necessary concerning recommendations for practice. The recommendations for the management of melanoma stages I to III were drawn up in 2005. At the request of the Société Française de Dermatologie, they have now been updated using the methodology for recommendations proposed by the Haute Autorité de Santé in France. In practice, the principal recommendations are as follows: for staging, it is recommended that the 7th edition of AJCC be used. The maximum excision margins have been reduced to 2 cm. Regarding adjuvant therapy, the place of interferon has been reduced and no validated emerging medication has yet been identified. Radiotherapy may be considered for patients in Stage III at high risk of relapse. The sentinel lymph node technique remains an option. Initial examination includes routine ultrasound as of Stage II , with other examinations being optional in stages IIC and III . A shorter strict follow‐up period (3 years) is recommended for patients, but with greater emphasis on imaging.